نتایج جستجو برای: ticagrelor
تعداد نتایج: 1574 فیلتر نتایج به سال:
BACKGROUND In patients undergoing primary percutaneous coronary intervention (PPCI) ticagrelor is superior to clopidogrel in reducing cardiovascular events. This study sought to evaluate the effect of clopidogrel pretreatment on the pharmacodynamics of ticagrelor in patients undergoing PPCI. METHODS We measured platelet reactivity using the VerifyNow P2Y12 assay at baseline, 1, 2, 4, 6, 12, 2...
BACKGROUND Ticagrelor, when compared with clopidogrel, reduced the 12-month risk of vascular death/myocardial infarction and stroke in patients with ST-elevation acute coronary syndromes intended to undergo primary percutaneous coronary intervention in the PLATelet inhibition and patient Outcomes (PLATO) trial. This prespecified ECG substudy explored whether ticagrelor's association with vascul...
OBJECTIVES The purpose of this study is to evaluate the efficacy and safety of ticagrelor and clopidogrel in patients with acute coronary syndrome undergoing coronary artery bypass graft surgery (CABG), as a post-randomization strategy. BACKGROUND Ticagrelor is a novel, reversibly binding, oral, direct-acting P2Y(12)-receptor antagonist. In the PLATO (Platelet Inhibition and Patient Outcomes)...
BACKGROUND No randomized head-to-head comparison of the efficacy and safety of ticagrelor and prasugrel has been published in the 7 years since the higher efficacy of these newer P2Y12 inhibitors were first demonstrated relative to clopidogrel. METHODS This academic study was designed to compare the efficacy and safety of prasugrel and ticagrelor in acute myocardial infarction treated with pr...
Abstract Funding Acknowledgements Type of funding sources: None. Introduction ST-elevation myocardial infarction (STEMI) requires starting dual antiplatelet therapy as soon possible. Potent P2Y12 inhibitors (prasugrel and ticagrelor) are preferred over clopidogrel. However, real world data is scarce when comparing potent inhibitors. Purpose To compare in-hospital clinical outcome between patien...
Dual antiplatelet treatment (DAPT) with aspirin and a P2Y12 receptor antagonist is essential for patients presenting with acute coronary syndrome (ACS) irrespective of their specific percutaneous coronary intervention (PCI). Clopidogrel (Bristol-Myers Squibb/Sanofi Pharmaceuticals, Bridgewater, NJ, USA), one of the most popular P2Y12 receptor antagonists of the past decade, has reduced the risk...
To compare the safety and efficacy of clopidogrel ticagrelor among patients with cytochrome P450 2C19*2 *3 mutations, to assess necessity pharmacogenetic testing is objective study.The study a two-center retrospective, observational cohort 425 patients. Compare differences different genotypes in rehospitalization owing original disease, major adverse cardiovascular events, initial readmission d...
Objetivo: Debater sobre o uso mais efetivo da antiagregação plaquetária após intervenção coronária percutânea. Métodos: A abordagem metodológica deste trabalho se propõe a um compilado de pesquisa bibliográfica qualitativa e caráter descritivo por meio uma revisão integrativa literatura nas bases dados PubMed Biblioteca Virtual em Saúde. Os descritores utilizados foram Platelet Aggregation Inhi...
Patients after percutaneous coronary intervention (PCI) with stent implantation and functional hyporesponsiveness to P2Y12 inhibitors are at higher risk of ischaemic events, particularly stent thrombosis (ST). It is currently not routine practice to assess the functional response to these agents. However, concern over functional hyporesponsiveness to clopidogrel has led to widespread uptake of ...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید